AbbVie has been striving to advance the standard of care in rheumatology for over 20 years. We are committed to creating a better tomorrow for patients everywhere.
In order to develop targeted therapies, AbbVie scientists have
demonstrated an unwavering focus on understanding what
makes the immune system turn on patients, causing RA and other
immune-mediated diseases. This knowledge allows us to target specific
enzymes involved in the process.
Delivering a one-two punch
Immune-mediated diseases are complex and often operate through
complementary pathways. We are exploring ways to inhibit multiple
disease pathways and enable greater precision through technologies
like antibody drug conjugates (ADCs) and combination therapies. First
developed for oncology, ADCs have the potential to deliver
anti-inflammatory medicine directly to a target. Combination therapies
may be needed to combat complex immune-mediated diseases by delivering
two therapies in
Real world impact
To help patients and health care professionals understand and
maximize the effectiveness of our medicines in the real world, we
investigate their impact outside of clinical
Transmits messages from the outside to the inside of a cell that drive an immune response.
Activates helper T-cells and certain macrophages, which produce additional cytokines that are involved in the inflammatory process.
Contributes to the induction and maintenance of the inflammatory immune response.
Involved in the maturation of B cells, which produce antibodies that help the body protect itself.